Skip to main content
Clinical Trials/CTRI/2020/10/028279
CTRI/2020/10/028279
Not yet recruiting
未知

Homeopathy as adjuvant to standard treatment protocol in management of corona virus infection- a randomized, placebo controlled, open label study

Central Council for Research in Homeopathy Ministry Ministry of Ayush0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Sponsor
Central Council for Research in Homeopathy Ministry Ministry of Ayush
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Central Council for Research in Homeopathy Ministry Ministry of Ayush

Eligibility Criteria

Inclusion Criteria

  • 1\. Age \> 18 years
  • 2\. All sexes
  • 3\. Case definitions for inclusion in the study will include moderate and severe cases as defined in the Guidance on appropriate treatment of suspect/confirmed case of COVID19 issued by Ministry of Health and Family Welfare, Govt of India on 07 Apr 2020\.
  • a. Moderate: Pneumonia with no signs of severe disease (Respiratory Rate 15 to 30/minute, SpO2 90%\-94%).
  • b. Severe: Severe Pneumonia (with respiratory rate \< 30/minute and/or SpO2 and requiring non\-invasive ventilatory support
  • 4\. Laboratory confirmed SARS CoV\-2 infection within last 10 days or SARS
  • 5\. CoV\-2 test result pending with a high clinical suspicion as defined by:
  • a. Cough of \<10d duration
  • b. Bilateral pulmonary infiltrates on chest X Ray / CT scan or new hypoxaemia defined as SpO2 \<94% on room air
  • c. No alternative explanation for respiratory symptoms

Exclusion Criteria

  • 1\. Children \< 18 years
  • 2\. Covid Positive patients with severe co\-morbidities
  • 3\. Pregnant and lactating women, infants and neonates
  • 4\. Not willing to give consent for adjuvant treatment
  • 5\. Inability to be contacted on D14 for clinical outcome assessment (unless died in hospital)
  • 6\. In the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments.
  • 7\. Symptoms of acute respiratory tract infection for \> 10d before randomisation, and covid status unknown
  • 8\. Death within 24 Hrs. of admission

Outcomes

Primary Outcomes

Not specified

Similar Trials